hfref
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| hfref [2026/03/16 04:07] – [Mx guidelines] gary1 | hfref [2026/08/30 10:43] (current) – [Introduction] gary1 | ||
|---|---|---|---|
| Line 15: | Line 15: | ||
| =====Introduction===== | =====Introduction===== | ||
| *the following applies to patients with LVEF < 41% | *the following applies to patients with LVEF < 41% | ||
| - | * NB. " | + | * NB. " |
| * NB. those with heart failure but normal LVEF > 49% are classified as [[hfpef]] | * NB. those with heart failure but normal LVEF > 49% are classified as [[hfpef]] | ||
| *SGLT2 inhibitors and MRAs can prevent or delay the development of heart failure in patients with diabetic kidney disease | *SGLT2 inhibitors and MRAs can prevent or delay the development of heart failure in patients with diabetic kidney disease | ||
hfref.txt · Last modified: 2026/08/30 10:43 by gary1